Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Nimira Alimohamed Clear advanced filters

  • Plasma ctDNA testing for FGFR alterations in metastatic urothelial carcinoma shows high concordance with tissue testing and identifies additional patients with actionable alterations. Here, the authors show that clinical uptake of ctDNA FGFR testing can be combined with tissue-based approaches.

    • David C. Müller
    • Andrew J. Murtha
    • Bernhard J. Eigl
    ResearchOpen Access
    Nature Communications
    Volume: 17, P: 1-10

  • Durable responses with first-line platinum-based chemotherapy for advanced-stage urothelial carcinoma are rare, and patient outcomes are poor. Recently, CheckMate 901 became the first phase III trial to establish a significant overall survival benefit from a combined chemoimmunotherapy approach in this disease setting. Herein, we discuss key findings from CheckMate 901 and their implications in the context of a rapidly evolving treatment landscape.

    • Nimira Alimohamed
    • Srikala S. Sridhar
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 21, P: 255-256

  • Many patients with muscle-invasive bladder cancer are currently excluded from cisplatin-based neoadjuvant chemotherapy owing to renal impairment. Here, Jiang and colleagues present an update on cisplatin-induced nephrotoxicity in muscle-invasive bladder cancer and highlight a multidisciplinary and patient-centred approach to treatment decision-making.

    • Di Maria Jiang
    • Shilpa Gupta
    • Srikala S. Sridhar
    Reviews
    Nature Reviews Urology
    Volume: 18, P: 104-114